- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Managing Bleeding Risk in Patients with ITP
A panelist discusses how bleeding risk assessment depends on platelet count levels (highest risk below 20,000), requiring careful medication history review to avoid drugs that impair platelet function like aspirin and NSAIDs.
Bleeding risk assessment in ITP patients directly correlates with platelet count - the lower the number, the higher the potential for bleeding. The risk is highest when counts fall below 10,000, with counts between 10,000-20,000 considered a gray area. Patients with counts below 20,000 face significantly elevated risks of spontaneous bleeding in critical areas including the gastrointestinal tract and brain.
A thorough medication history is essential as certain medications impact platelet function, further increasing bleeding risk. These include over-the-counter options like aspirin, cold medicines containing aspirin, and nonsteroidal anti-inflammatory drugs (NSAIDs). Patient education should emphasize avoiding these medications when platelet counts are low.
Healthcare providers should conduct detailed medication reviews including over-the-counter products, frequency of use, and reasons for use. Identifying potential substitutes that won't affect platelet function is critical when managing patients with very low platelet counts to minimize bleeding complications.
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Zilucoplan Shows Rapid, Durable, Steroid-Sparing Benefits in gMG
June 12th 2025Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).
Read More
